CD39 tissue-resident memory CD8 T cells with a clonal overlap across compartments mediate antitumor immunity in breast cancer.

Despite being a standard treatment option in breast cancer, immune checkpoint inhibitors (ICIs) are only efficacious for a subset of patients. To gain a better understanding of the antitumor immune response in breast cancer, we examined the heterogeneity of CD8 T cells in tumors, metastatic lymph nodes (mLNs), and peripheral blood from patients with early breast cancer ( = 131). Among tissue-resident memory CD8 T (T) cells, including virus- and tumor-specific CD8 T cells, CD39 expression was observed in a tumor-specific and exhausted subpopulation in both tumors and mLNs. CD39 T cells from tumors and mLNs exhibited a phenotypic similarity and clonally overlapped with each other. Moreover, tumor or mLN CD39 T cells clonally overlapped with CD39 T and non-T cells in the same compartment, implying a tissue-specific differentiation process. These inter-subpopulationally overlapping CD39 T clonotypes were frequently detected among effector memory CD8 T cells in peripheral blood, suggesting a systemic clonal overlap. CD39 T cell enrichment was heterogeneous among molecular subtypes of breast cancer, which is associated with the different role of antitumor immune responses in each subtype. In vitro blockade of PD-1 and/or CTLA-4 effectively restored proliferation of CD39 T cells and enhanced cytokine production by CD8 T cells from tumors or mLNs, particularly in the presence of CD39 T enrichment. This suggests that CD39 T cells have a capacity for functional restoration upon ICI treatment. Thus, our study indicates that CD39 T cells with a clonal overlap across compartments are key players in antitumor immunity in breast cancer.